Svb Wealth LLC Tcr2 Therapeutics Inc. Transaction History

Svb Wealth LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$4.58 - $8.34 $192,744 - $350,980	-42,084 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$8.44 - $18.35 $355,180 - $772,223	-42,083 Reduced 50.0%	42,084 $358,000
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $190,897 - $287,451	11,633 Added 16.04%	84,167 $1.38 Million
Q4 2020 Feb 10, 2021	SELL	$19.0 - $32.63 $178,125 - $305,906	-9,375 Reduced 11.45%	72,534 $2.24 Million
Q2 2020 Aug 05, 2020	BUY	$6.51 - $16.85 $214,400 - $554,937	32,934 Added 67.25%	81,909 $1.26 Million

Q4 2019 Feb 13, 2020	BUY	$12.17 - $17.88 $596,025 - $875,673	48,975 New	48,975 $699,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Svb Wealth LLC, based on Form 13F filings with the SEC.

Stay updated on Svb Wealth LLC with notifications on news.